incorrectly interpreted to be irreversible if only stress-reinjection images were acquired. Dr. Freedman's finding of low differential uptake in 11% of their patients after reinjection appears to confirm our results.
1. Dilsizian V, Freedman NMT, Bacharach SL, Perrone-Filardi P, Bonow RO: Regional thallium uptake in irreversible defects: Magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium. Letter To the Editor Beuckelmann et al recently published a report in Circulation' showing that peak systolic intracellular calcium measured by fura-2 was diminished in single ventricular cells from patients with heart failure. Although the experimental findings were interesting, the suggestion by the authors that the major defect in contractile failure is a diminished intracellular calcium concentration was distressing. The authors propose that diminished calcium availability might explain impaired contractile performance in human heart failure because calcium concentration is intimately related to force production; it is important to note, however, that this conclusion is weakened by the fact that Beuckelmann et al did not measure force or cell shortening during excitation in their cells. These results are in contrast to those obtained by other investigators who used different experimental techniques and reported similar systolic calcium concentrations in myopathic and control human myocardium.2-6 More importantly, we and others have found similar force production in control and myopathic hearts, and it has been clearly demonstrated that in failing human myocardium, there is a significant increase in resting intracellular calcium concentration. The clinical extrapolation of the data proposed by the authors was especially alarming because they suggest that agents that increase intracellular calcium would be beneficial in patients with failure. Recently, however, the PROMISE trials7 have indicated that such agents may not be useful or may even be harmful to patients with failure. We feel that it is very important to alert the reader that the issue of whether intracellular calcium release is reduced during excitation-contraction coupling in heart failure is still controversial and that therapeutic decisions should not be based on this one report.
Reply
We appreciate the comments by Dr. Morgan and Dr. Gwathmey concerning the interpretation of our data. There may have been some misunderstanding, however, as our results do not indicate a generally diminished intracellular [Ca21], concentration. In fact, we have shown that resting [Ca2+]J levels are increased but that peak systolic [Ca21]1 transients are diminished in heart cells from patients with heart failure. Therefore, we completely agree that pharmacological agents that would simply increase resting [Ca2+]1 might be harmful. An increase in resting [Ca 2+I1 might further reduce Ca2' release from the sarcoplasmic reticulum through Ca2+-dependent inactivation of the Ca2' release channel as shown by Fabiato.1 Therefore, in our paper we have put forward the idea that pharmacological agents that enhance Ca21 uptake by the sarcoplasmic reticulum would be expected to be beneficial, which agrees with suggestions in earlier papers from Drs. Morgan and Gwathmey. Whether such a pharmacological intervention is beneficial in heart failure, of course, has to await a clinical trial. 
